Rein Therapeutics, Inc. — Form 8-K
Filed September 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Rein Therapeutics announced enrollment in the RENEW Phase 2 clinical trial (NCT06968845) for LTI-03, a novel inhaled caveolin scaffolding domain peptide for idiopathic pulmonary fibrosis (IPF). The Phase 1b trial (NCT05954988) was completed with safety/tolerability data: 5mg and 10mg doses were well-tolerated with no treatment-related serious adverse events in 24 subjects over 14 days; exploratory biomarkers (SP-D, TSLP, IL-11, COL1A1, CXCL7, GAL-7) showed directional consistency or nominal significance with preclinical findings, particularly at the 10mg dose. Phase 2 data is expected in H2 2026.
Why this rating
Phase 2 initiation is a significant clinical milestone for a $32.3M-market-cap biotech; positive Phase 1b safety profile and biomarker signals reduce execution risk. IPF market is large (Ofev >$4B annually), but clinical success unproven.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.89 ▲ 0.00% | at our read · unknown $0.89 | +10 min · unknown $0.89 ▲ 0.00% | +30 min · unknown $0.89 ▲ 0.00% | +1 hr · unknown $0.89 ▲ 0.00% | +4 hrs pending |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.